From Symptoms to Solutions: Transforming Menopause Treatment with Marci English of Astellas Pharma

Xtalks Life Science Podcast

A tartalmat a Xtalks biztosítja. Az összes podcast-tartalmat, beleértve az epizódokat, grafikákat és podcast-leírásokat, közvetlenül a Xtalks vagy a podcast platform partnere tölti fel és biztosítja. Ha úgy gondolja, hogy valaki az Ön engedélye nélkül használja fel a szerzői joggal védett művét, kövesse az itt leírt folyamatot https://hu.player.fm/legal.

2M ago 28:17

MP4•Epizód kép

In this episode, Ayesha spoke with Marci English, Vice President and Head of BioPharma Development at Astellas Pharma about a groundbreaking new treatment that addresses the underlying mechanisms of menopause symptoms.

In May 2023, Astellas received FDA approval for fezolinetant (commercial name Veozah) for the treatment of moderate to severe vasomotor symptoms due to menopause. The therapy is the first nonhormonal neurokinin 3 (NK3) receptor antagonist approved to treat vasomotor symptoms associated with menopause, which include hot flashes and night sweats.

Tune into the episode to learn about the latest on fezolinetant one year after its approval, including its reception from healthcare providers and patients.

For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/
Follow Us on Social Media

Twitter: https://twitter.com/Xtalks
Instagram: https://www.instagram.com/xtalks/
Facebook: https://www.facebook.com/Xtalks.Webinars/
LinkedIn: https://www.linkedin.com/company/xtalks-webconferences
YouTube: https://www.youtube.com/c/XtalksWebinars/featured

174 epizódok

#Science #Biology #Xtalks #Pharma #Biotech #Biotechnology #Medical Device #Drug Safety #Pharmaceutical Manufacturing #Clinical Research #Clinical Trials #Drug Development #Laboratory #Podcasting Education #Pharmaceutical #Life Sciences